We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viracta Therapeutics Inc | NASDAQ:VIRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0298 | -3.55% | 0.8102 | 0.40 | 0.88 | 0.84 | 0.80 | 0.8212 | 33,087 | 05:00:07 |
From May 2021 to May 2024
By Michael Dabaie
Viracta Therapeutics Inc. said the U.S. Food and Drug Administration granted its product candidate nanatinostat and valganciclovir, or Nana-val, orphan drug designation for the treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma.
DLBCL is the most common subtype of non-Hodgkin lymphoma in the U.S. and worldwide, the company said.
Viracta shares rose 9.5% to $5.30 in premarket trading.
This is the fourth U.S. FDA orphan drug designation granted for Nana-val. Viracta has previously received FDA orphan drug designation for the treatment of T-cell lymphoma, post-transplant lymphoproliferative disorder and plasmablastic lymphoma.
The FDA grants orphan drug designations to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 29, 2021 08:35 ET (13:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Viracta Therapeutics Chart |
1 Month Viracta Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
